HRP20211824T1 - Modulatori aktivnosti komplementa - Google Patents
Modulatori aktivnosti komplementa Download PDFInfo
- Publication number
- HRP20211824T1 HRP20211824T1 HRP20211824TT HRP20211824T HRP20211824T1 HR P20211824 T1 HRP20211824 T1 HR P20211824T1 HR P20211824T T HRP20211824T T HR P20211824TT HR P20211824 T HRP20211824 T HR P20211824T HR P20211824 T1 HRP20211824 T1 HR P20211824T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- use according
- subject
- hemolysis
- eculizumab
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 206010018910 Haemolysis Diseases 0.000 claims 4
- 230000008588 hemolysis Effects 0.000 claims 4
- 229960002224 eculizumab Drugs 0.000 claims 3
- 108010028773 Complement C5 Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Steroid Compounds (AREA)
- Amplifiers (AREA)
Claims (10)
1. Polipeptid koji se sastoji od SEQ ID NO: 194 ili SEQ ID NO: 184 za uporabu u postupku liječenja poremećaja povezanog s C5 komplementom, postupak koji se sastoji od primjene polipeptida u dozi od oko 0.1 mg/kg do oko 10 mg /kg pri čemu je hemoliza u subjektu smanjena za najmanje 50% u odnosu na razine hemolize koje su prethodno uočene kod navedenog subjekta.
2. Polipeptid za uporabu prema zahtjevu 1, naznačen time što se navedeni polipeptid daje navedenom subjektu u dozi od oko 0.3 mg/kg do oko 3 mg/kg.
3. Polipeptid za uporabu prema zahtjevu 2, naznačen time što se navedeni polipeptid daje navedenom subjektu u dozi od oko 0.3 mg/kg.
4. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-3, naznačen time što se navedena primjena provodi svakodnevno.
5. Polipeptid za uporabu prema zahtjevu 4, naznačen time što se navedena primjena provodi sedam dana.
6. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-5, naznačen time što je poremećaj povezan s C5-komplementom paroksizmalna noćna hemoglobinurija.
7. Polipeptid za uporabu prema zahtjevu 6, naznačen time što je navedeni subjekt prethodno liječen ECULIZUMAB-om.
8. Polipeptid za uporabu prema zahtjevu 6, naznačen time što navedeni subjekt također prima tretman s ECULIZUMAB-om.
9. Polipeptid za uporabu prema zahtjevu 7 ili 8, naznačen time što je liječenje ECULIZUMAB-om neučinkovito.
10. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-9, naznačen time što je hemoliza kod subjekta smanjena za najmanje 90% u odnosu na razine hemolize koje su prethodno uočene kod navedenog subjekta.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562108772P | 2015-01-28 | 2015-01-28 | |
PCT/US2015/035473 WO2015191951A2 (en) | 2014-06-12 | 2015-06-12 | Modulation of complement activity |
US201562185298P | 2015-06-26 | 2015-06-26 | |
PCT/US2016/015412 WO2016123371A1 (en) | 2015-01-28 | 2016-01-28 | Modulators of complement activity |
EP16744125.2A EP3250230B9 (en) | 2015-01-28 | 2016-01-28 | Modulators of complement activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211824T1 true HRP20211824T1 (hr) | 2022-03-04 |
Family
ID=56544343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211824TT HRP20211824T1 (hr) | 2015-01-28 | 2016-01-28 | Modulatori aktivnosti komplementa |
Country Status (14)
Country | Link |
---|---|
US (6) | US9937222B2 (hr) |
EP (2) | EP3988110A1 (hr) |
JP (2) | JP6640229B2 (hr) |
CY (1) | CY1124761T1 (hr) |
ES (1) | ES2900998T3 (hr) |
HK (1) | HK1246672A1 (hr) |
HR (1) | HRP20211824T1 (hr) |
HU (1) | HUE056613T2 (hr) |
LT (1) | LT3250230T (hr) |
PL (1) | PL3250230T3 (hr) |
PT (1) | PT3250230T (hr) |
RS (1) | RS62630B9 (hr) |
SI (1) | SI3250230T1 (hr) |
WO (1) | WO2016123371A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4223317A3 (en) * | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
EP3988110A1 (en) | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
MX2018007352A (es) * | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
BR112019011053A2 (pt) * | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
PL3612208T3 (pl) | 2017-04-21 | 2023-07-24 | Volution Immuno Pharmaceuticals Sa | Coversin do leczenia autoimmunologicznych chorób pęcherzowych |
EP3612206A1 (en) * | 2017-04-21 | 2020-02-26 | Volution Immuno Pharmaceuticals SA | Coversin for the treatment of cicatrising eye inflammatory disorders |
SG11202103972SA (en) | 2018-10-22 | 2021-05-28 | Ra Pharmaceuticals Inc | Neurological disease treatment with zilucoplan |
CN113966224A (zh) | 2019-06-04 | 2022-01-21 | Ra制药公司 | 采用补体抑制剂的炎性疾病治疗 |
JP6773930B1 (ja) | 2019-08-09 | 2020-10-21 | 住友化学株式会社 | 液晶ポリエステル樹脂成形体、液晶ポリエステル樹脂ペレット、及び液晶ポリエステル樹脂ペレットの製造方法 |
EP4028126A1 (en) | 2019-09-12 | 2022-07-20 | RA Pharmaceuticals, Inc. | Neurological disease treatment with complement inhibitors |
WO2022177635A2 (en) * | 2021-02-22 | 2022-08-25 | Ra Pharmaceuticals, Inc. | Compositions and methods for microbial disease treatment |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271068A (en) | 1968-05-10 | 1981-06-02 | Ciba-Geigy Corporation | Process for the manufacture of cystine-containing peptides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
US4216141A (en) | 1978-07-19 | 1980-08-05 | The Salk Institute For Biological Studies | Method for cyclization of peptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン,インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
US5585353A (en) | 1990-02-02 | 1996-12-17 | The Rockefeller University | Antibiotic peptides containing D-amino acids |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
JPH08510325A (ja) | 1993-05-28 | 1996-10-29 | カイロン コーポレイション | 生物学的に活性なペプチド配列の選択方法 |
DK0710243T3 (da) | 1993-06-29 | 2000-10-16 | Ferring Bv | Syntese af cykliske peptider |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
EP0962527B1 (en) | 1996-10-17 | 2004-08-04 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
EP0896001A1 (en) | 1997-08-08 | 1999-02-10 | Daicel Chemical Industries, Ltd. | Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
IL140930A0 (en) | 1998-08-07 | 2002-02-10 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
CA2524534C (en) | 2003-05-15 | 2012-12-11 | Sek Chung Fung | Methods and compositions for the prevention and treatment of sepsis |
US7348401B2 (en) | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
CA2537029C (en) | 2003-11-26 | 2013-03-12 | Likan Liang | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
US20060027059A1 (en) | 2004-08-09 | 2006-02-09 | Chih-Ching Hsien | Extendable handle device |
US20090054623A1 (en) | 2004-12-17 | 2009-02-26 | Neose Technologies, Inc. | Lipo-Conjugation of Peptides |
PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
EP1874289A2 (en) | 2005-03-29 | 2008-01-09 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
DK1888031T3 (da) | 2005-06-06 | 2013-02-18 | Camurus Ab | GLP-1-analogformuleringer |
KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
EP1876183A1 (en) | 2006-07-04 | 2008-01-09 | Technische Universität München | Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins |
US8703136B2 (en) | 2006-10-10 | 2014-04-22 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
CA2680760A1 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
JP2010526074A (ja) | 2007-04-30 | 2010-07-29 | アルコン リサーチ, リミテッド | 補体因子dのインヒビターを用いる加齢黄斑変性の処置 |
KR20150029002A (ko) | 2007-06-07 | 2015-03-17 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법 |
US20110142837A1 (en) | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
KR20150080007A (ko) | 2007-10-02 | 2015-07-08 | 포텐시아 팔마큐티칼스, 인크. | 겔로부터 콤스타틴 유사체의 지속적 운반 |
WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
US20110190221A1 (en) | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
EP2324048A2 (en) | 2008-07-30 | 2011-05-25 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
PT2894165T (pt) | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
CN106390117A (zh) | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
CN102958535A (zh) | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
WO2011073328A1 (en) | 2009-12-16 | 2011-06-23 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
US9172511B2 (en) | 2009-12-24 | 2015-10-27 | Samsung Electronics Co., Ltd. | Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network |
US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
WO2011137363A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
EP2694108B1 (en) | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
CN102321170B (zh) | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | 利拉鲁肽变构体及其缀合物 |
WO2013052736A2 (en) | 2011-10-06 | 2013-04-11 | The Medicines Company | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
WO2013126006A1 (en) | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
AU2013222343B2 (en) * | 2012-02-21 | 2016-10-06 | Chevron U.S.A. Inc. | System and method for measuring well flow rate |
US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
CA2873511A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
US20150330989A1 (en) | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
WO2015140304A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
EP4223317A3 (en) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
WO2016118652A1 (en) | 2015-01-21 | 2016-07-28 | Pacira Pharmaceuticals, Inc. | Multivesicular liposome formulations of tranexamic acid |
EP3988110A1 (en) * | 2015-01-28 | 2022-04-27 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
MX2018007352A (es) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
US20200282024A1 (en) | 2017-09-11 | 2020-09-10 | Ra Pharmaceuticals, Inc. | Formulations for compound delivery |
CN111683672A (zh) | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
BR112021017820A2 (pt) | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
-
2016
- 2016-01-28 EP EP21205542.0A patent/EP3988110A1/en active Pending
- 2016-01-28 RS RS20211470A patent/RS62630B9/sr unknown
- 2016-01-28 HU HUE16744125A patent/HUE056613T2/hu unknown
- 2016-01-28 US US15/547,085 patent/US9937222B2/en active Active
- 2016-01-28 JP JP2017539419A patent/JP6640229B2/ja active Active
- 2016-01-28 PL PL16744125T patent/PL3250230T3/pl unknown
- 2016-01-28 SI SI201631403T patent/SI3250230T1/sl unknown
- 2016-01-28 HR HRP20211824TT patent/HRP20211824T1/hr unknown
- 2016-01-28 ES ES16744125T patent/ES2900998T3/es active Active
- 2016-01-28 LT LTEPPCT/US2016/015412T patent/LT3250230T/lt unknown
- 2016-01-28 PT PT167441252T patent/PT3250230T/pt unknown
- 2016-01-28 WO PCT/US2016/015412 patent/WO2016123371A1/en active Application Filing
- 2016-01-28 EP EP16744125.2A patent/EP3250230B9/en active Active
-
2018
- 2018-02-26 US US15/905,158 patent/US10328115B2/en active Active
- 2018-05-15 HK HK18106263.7A patent/HK1246672A1/zh unknown
-
2019
- 2019-04-24 US US16/393,393 patent/US10588936B2/en active Active
- 2019-12-25 JP JP2019233666A patent/JP6915034B2/ja active Active
-
2020
- 2020-01-30 US US16/776,551 patent/US10918691B2/en active Active
-
2021
- 2021-01-07 US US17/143,232 patent/US11707503B2/en active Active
- 2021-12-06 CY CY20211101063T patent/CY1124761T1/el unknown
-
2023
- 2023-06-01 US US18/204,907 patent/US20240156896A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US9937222B2 (en) | 2018-04-10 |
HK1246672A1 (zh) | 2018-09-14 |
EP3250230A1 (en) | 2017-12-06 |
RS62630B9 (sr) | 2022-04-29 |
US20180193408A1 (en) | 2018-07-12 |
SI3250230T1 (sl) | 2022-01-31 |
EP3988110A1 (en) | 2022-04-27 |
ES2900998T3 (es) | 2022-03-21 |
US20190307835A1 (en) | 2019-10-10 |
US20200155639A1 (en) | 2020-05-21 |
LT3250230T (lt) | 2021-12-27 |
EP3250230A4 (en) | 2019-01-23 |
JP6640229B2 (ja) | 2020-02-05 |
US20180021402A1 (en) | 2018-01-25 |
US10588936B2 (en) | 2020-03-17 |
CY1124761T1 (el) | 2022-11-25 |
JP2020073526A (ja) | 2020-05-14 |
EP3250230B1 (en) | 2021-11-10 |
US20210283212A1 (en) | 2021-09-16 |
US20240156896A1 (en) | 2024-05-16 |
HUE056613T2 (hu) | 2022-02-28 |
EP3250230B9 (en) | 2022-02-23 |
US10328115B2 (en) | 2019-06-25 |
PL3250230T3 (pl) | 2022-02-14 |
JP2018509388A (ja) | 2018-04-05 |
PT3250230T (pt) | 2021-12-07 |
JP6915034B2 (ja) | 2021-08-04 |
US11707503B2 (en) | 2023-07-25 |
US10918691B2 (en) | 2021-02-16 |
WO2016123371A1 (en) | 2016-08-04 |
RS62630B1 (sr) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211824T1 (hr) | Modulatori aktivnosti komplementa | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
PH12017500746A1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
BR112017023904A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
EA201992329A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
BR112018069601A2 (pt) | derivados de indolina substituídos como inibidores da replicação viral da dengue | |
MX2019012884A (es) | Terapia de combinacion. | |
EA201992334A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
BR112017015123A2 (pt) | derivados de indol como inibidores da replicação viral do dengue | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
MX2016006657A (es) | Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis. | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica |